Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine

Antiviral Therapy

Volumn 16, Issue 1, 2011, Pages 115-118

  Hamers, Raph L ^a,b   Wensing, Annemarie M J ^c   Back, Nicole K T ^d   Arcilla, Maria S ^a   Frissen, Jos P H ^a  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DARUNAVIR; ENFUVIRTIDE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OFLOXACIN; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KAPOSI SARCOMA; MALE; MULTICENTER STUDY; MYCOPLASMOSIS; NONHUMAN; PRIORITY JOURNAL; SIERRA LEONE; SYMPTOM; VIRUS MUTATION;

ADULT; DRUG RESISTANCE, MULTIPLE, VIRAL; GENETIC VARIATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MALE; MONITORING, PHYSIOLOGIC; MUTATION; NEVIRAPINE; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; SIERRA LEONE; STAVUDINE; TREATMENT FAILURE;

EID: 79951486031     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1683     Document Type: Article

References (25)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2009. (Updated 4 November 2009. Accessed 1 April 2010.) Available from http://www.who.int/hiv/ pub/tuapr-2009-en.pdf
2. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
3. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224. (Pubitemid 40962502)
4. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371:1603-1611. (Pubitemid 351626844)
5. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. (Updated 15 July 2010. Accessed 1 August 2010.) Available from http://www.who.int/hiv/pub/arv/adult2010/en/index.html
6. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-417.
7. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
8. Stanford University HIV Drug Resistance Database. (Accessed 1 April 2010.) Available from http://hivdb.stanford.edu/index.html
9. Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10:791-802. (Pubitemid 41652973)
10. Flandre P, Descamps D, Joly V, et al. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received. Antivir Ther 2003; 8:65-72. (Pubitemid 36368304)
11. Turner D, Brenner BG, Routy JP, Petrella M, Wainberg MA. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 2004; 27:31-39. (Pubitemid 40090987)
12. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000; 44:2109-2117. (Pubitemid 30484434)
13. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-4977.
14. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
15. Hawkins CA, Chaplin B, Idoko J, et al. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009; 52:228-234.
16. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
17. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531.
18. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452. (Pubitemid 46147631)
19. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-484.
20. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 2009; 200:1202-1206.
21. Henry M, Thuret I, Solas C, Genot S, Colson P, Tamalet C. Vertical transmission of multidrug-resistant Q151M human immunodeficiency virus type 1 strains. Pediatr Infect Dis J 2008; 27:278-280.
22. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12:83-88. (Pubitemid 46340429)
23. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-287. (Pubitemid 41533067)
24. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
25. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814. (Pubitemid 44223104)